Fusion Pharmaceuticals company information, Employees & Contact Information

Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer PR Newswire

FPI-2265 Dosing Commences in Phase 2 AlphaBreak Trial for mCRPC Targeted Oncology

Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates PR Newswire

Acquisition of Fusion Pharmaceuticals Completed PR Newswire

Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates PR Newswire

Fusion Pharmaceuticals Announces First Quarter 2023 Financial Results and Clinical Program Updates PR Newswire

Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024 PR Newswire

Fusion Pharmaceuticals Announces Third Quarter 2022 Financial Results and Clinical Program Updates PR Newswire

Fusion Pharmaceuticals Announces Opening of Radiopharmaceutical Manufacturing Facility to Produce Targeted Alpha Therapies for Cancer PR Newswire

Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer PR Newswire

Fusion Pharmaceuticals to Present Interim Data from Phase 1 Trial of FPI-1434 in Patients with Solid Tumors Expressing IGF-1R PR Newswire

Fusion Pharmaceuticals and TRIUMF Announce Expanded R&D Collaboration for Actinium Supply Production PR Newswire

Fusion Pharmaceuticals to Present Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the 2024 AACR Annual Meeting PR Newswire

Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer PR Newswire

Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2068, a Novel Targeted Alpha Therapy for EGFR-cMET Expressing Cancers PR Newswire

Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-1966, an Investigational Radiopharmaceutical for the Treatment of Head and Neck and Bladder Cancers Expressing FGFR3 PR Newswire

Fusion Pharmaceuticals Announces IND Clearance for FPI-2068, a Jointly Developed Novel Targeted Alpha Therapy PR Newswire

Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors PR Newswire

Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-2059, an Investigational Small Molecule-Based Radiopharmaceutical Targeting Solid Tumors Expressing NTSR1 PR Newswire

Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of FPI-2059, a Targeted Alpha Therapy (TAT) for the Treatment of Solid Tumors Expressing NTSR1 PR Newswire

Fusion Pharmaceuticals Strengthens Actinium Supply with Onsite Isotope Production through Expanded BWXT Medical Collaboration PR Newswire

Fusion Pharmaceuticals Appoints Industry Veteran Christopher Leamon, Ph.D., as Chief Scientific Officer PR Newswire

Fusion Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate Fusion's Targeted Alpha Therapy (TAT) in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients With Solid Tumors Expressing IGF-1R PR Newswire

Fusion Pharmaceuticals Appoints Mohit Rawat as President and Chief Business Officer PR Newswire

Fusion Pharmaceuticals Massachusetts Biotechnology Council

Fusion Pharmaceuticals and Niowave Announce Actinium-225 Collaboration and Supply Agreement PR Newswire

Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1/2 Study of FPI-1966 In Patients with Advanced Solid Tumors Expressing FGFR3 PR Newswire